<DOC>
	<DOCNO>NCT01218906</DOCNO>
	<brief_summary>The purpose study detect acute febrile episodes dengue infection five Asian country , assess dengue seroprevalence , assess surveillance infrastructure investigational site anticipation Phase 3 efficacy trial vaccine prevent dengue infection . The primary objective : - To identify acute febrile episode among cohort order detect presence dengue infection . - To develop operational infrastructure potential Phase III dengue efficacy trial site . - To describe dengue seroprevalence among cohort baseline end study .</brief_summary>
	<brief_title>Prospective Surveillance Febrile Illness Dengue-Endemic Areas Asia</brief_title>
	<detailed_description>All participant make two visit study site , enrollment visit termination visit . Additional visit make febrile episode occur : acute visit convalescent visit . Participants parents/guardians contact weekly monitor occurrence febrile episodes ensure appropriate assessment care . No vaccine provide administer study .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 14 year day inclusion resident site zone Subject good health , base medical history physical examination Assent form sign date subject ( required local regulation ) , informed consent form sign dated parent ( ) another legally acceptable representative ( subject and/or independent witness require local regulation ) Subject able attend schedule visit comply study procedure For female childbearing potential , use effective method contraception abstinence least 4 week prior enrollment . Exclusion Criteria : Known pregnancy Enrollment Visit Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede enrollment Planned participation another clinical trial present study period Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Selfreported seropositivity Human Immunodeficiency Virus ( HIV ) infection Chronic illness , opinion Investigator , stage might interfere study conduct completion Current alcohol abuse drug addiction may interfere subject 's ability comply study procedure Receipt blood bloodderived product past 3 month Receipt vaccine 4 week precede day enrollment except pandemic influenza vaccination , may receive least 2 week enrollment Planned receipt vaccine 4 week follow enrollment Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator . Temporary Contraindications A prospective subject include study follow condition and/or symptom resolve : Febrile illness ( temperature ≥ 38.0°C ) moderate severe acute illness/infection ( accord Investigator judgment ) day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Dengue Fever Fever Dengue Infection</keyword>
</DOC>